User:Jessica Gauldin/Sandbox1
From Proteopedia
Line 6: | Line 6: | ||
== Structure == | == Structure == | ||
There are 5 classes of dopamine receptors (D1, D2, D3, D4, D5), all of which have similar structures since they are all part of a G-protein coupled receptor family. This means that the portion of the receptor spanning the inner part of the cell’s membrane is composed of seven membrane-spanning G-protein (guanine nucleotide binding) domains (Beaulieu). | There are 5 classes of dopamine receptors (D1, D2, D3, D4, D5), all of which have similar structures since they are all part of a G-protein coupled receptor family. This means that the portion of the receptor spanning the inner part of the cell’s membrane is composed of seven membrane-spanning G-protein (guanine nucleotide binding) domains (Beaulieu). | ||
- | The D1 and D5 dopamine receptors are 80% homologous in their transmembrane domains, whereas the D3 and D4 dopamine receptors are 75 and 53% homologous, respectively, with the D2 receptor (Beaulieu). Meaning, all of the dopamine receptors have similar structures. | + | The D1 and D5 dopamine receptors are 80% homologous in their transmembrane domains, whereas the D3 and D4 dopamine receptors are 75 and 53% homologous, respectively, with the D2 receptor (Beaulieu, 2011). Meaning, all of the dopamine receptors have similar structures. |
Proteins are a long chain of various amino acid sequences. Inside the binding pocket, the residues that are used to bind dopamine to the receptor are Asp-114, Ser-193, Ser-197, Phe-110, Met-117, Cys-118, Phe-164, Phe-189, Val-190, Trp-386, Phe-390, and Hist-394. Dopamine binds to the top of the receptor structure. The pocket formed by these residues is hydrophobic and the residues are consistent among human dopamine receptors (Kalani et al., 2004). In the dopamine receptor, both the N-terminus (amino end of the polypeptide chain) and the C-terminus (carboxyl-group end of the polypeptide chain) are located on the extracellular portions of the cell membrane. Furthermore, all dopamine receptors contain two cysteine amino acids on their extracellular portions whose disulfide bridge helps stabilize this protein (Missale et al., 1998). | Proteins are a long chain of various amino acid sequences. Inside the binding pocket, the residues that are used to bind dopamine to the receptor are Asp-114, Ser-193, Ser-197, Phe-110, Met-117, Cys-118, Phe-164, Phe-189, Val-190, Trp-386, Phe-390, and Hist-394. Dopamine binds to the top of the receptor structure. The pocket formed by these residues is hydrophobic and the residues are consistent among human dopamine receptors (Kalani et al., 2004). In the dopamine receptor, both the N-terminus (amino end of the polypeptide chain) and the C-terminus (carboxyl-group end of the polypeptide chain) are located on the extracellular portions of the cell membrane. Furthermore, all dopamine receptors contain two cysteine amino acids on their extracellular portions whose disulfide bridge helps stabilize this protein (Missale et al., 1998). | ||
== Function == | == Function == | ||
- | Dopamine is a neurotransmitter naturally found in the brain and acts specifically on dopamine receptors. It is classified as a catecholamine, meaning it is made from the amino acid, tyrosine. Dopamine is the precursor to both norepinephrine and epinephrine, which innervate the sympathetic nervous system, therefore its effects in the body are widespread ( | + | Dopamine is a neurotransmitter naturally found in the brain and acts specifically on dopamine receptors. It is classified as a catecholamine, meaning it is made from the amino acid, tyrosine. Dopamine is the precursor to both norepinephrine and epinephrine, which innervate the sympathetic nervous system, therefore its effects in the body are widespread (Dopamine,2015). For instance, when these receptors are activated in the renal vasculature, this leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output. |
- | Activation of dopamine receptors can either lead to an excitatory (D1, D5) or inhibitory (D2, D3, D4) response in the brain (Brown, 2015). When the excitatory receptors are activated, this activates adenylyl cyclase, a regulatory enzyme, which then increases the concentration of cAMP inside the cell (Dopamine Receptor). Activation of D2-like receptors generates an inhibitory response by preventing the formation of cAMP by inhibiting the adenylyl cyclase enzyme (Dopamine Receptor). | + | Activation of dopamine receptors can either lead to an excitatory (D1, D5) or inhibitory (D2, D3, D4) response in the brain (Brown, 2015). When the excitatory receptors are activated, this activates adenylyl cyclase, a regulatory enzyme, which then increases the concentration of cAMP inside the cell (Dopamine Receptor,2015). Activation of D2-like receptors generates an inhibitory response by preventing the formation of cAMP by inhibiting the adenylyl cyclase enzyme (Dopamine Receptor,2015). |
== Ligands == | == Ligands == |
Revision as of 23:56, 16 November 2015
Dopamine Receptor
|
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
3. Beaulieu, Jean-Martin, and Gainetdinov, Raul R. "The Physiology, Signaling, and Pharmacology of Dopamine Receptors." Pharmacological Reviews 63.1 (2011): 182-217.
4. Brisch, Ralf, Arthur Saniotis, Rainer Wolf, Hendrik Bielau, Hans-Gert Bernstein, Johann Steiner, Bernhard Bogerts, Katharina Braun, Zbigniew Jankowski, Jaliya Kumaratilake, Maciej Henneberg, and Tomasz Gos. "The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue." Frontiers in Psychiatry. Frontiers Media S.A., 19 May 2014. Web. 16 Nov. 2015.
5. Brown, Justin. Drugs and Addiction. James Madison University. 14 Oct. Lecture. 2015.
6. Brown, Justin. Neurotransmitters. James Madison University. 16 Oct. Lecture. 2015.
7. "Dopamine." Dopamine. PubChem, 24 Oct. 2015. Web. 27 Oct. 2015.
8. "Dopamine Receptor." 2015. NCBI. Web. 15 Nov. 2015.
9. Granado, N., Ares-Santos, S., & Moratalla, R. (2013, May 27). The Role of Dopamine Receptors in the Neurotoxicity of Methamphetamine. NCBI Journal of Internal Medicine. 16 Nov 2015.
10. How Does Cocaine Produce its Effects? (n.d.). NIH National Institute of Drug Abuse. 16 Nov 2015.
11. Kalani, M., Vaidehi, N., Hall, S., Trabanino, R., Freddolino, P., Kalani, M., Floriano, W., Kam, V., Goddard, W.(2004). The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proceedings of the National Academy of Sciences, 101(11), 3815-3820. doi:10.1073/pnas.0400100101
12. Kim, Jong-Hoon, and Johnathan Auerbach. "Dopamine Neurons Derived from Embryonic Stem Cells Function in an Animal Model of Parkinson's Disease." Nature.com. Nature Publishing Group, 4 July 2002. Web. 16 Nov. 2015.
13. Kish, S. (2008, June 17). Pharmacologic Mechanisms of Crystal Meth. NCBI Canadian Medical Journal Association.16 Nov 2015.
14. Missale, C., Nash, S., Robinson, S., Jaber, M., & Caron, M. (1998). Dopamine Receptors: From Structure to Function. Physiological Reviews, 78(1), 189-225. 16 Nov 2015.
15. "Treatment Statistics." DrugFacts:. NIH, Mar. 2011. Web. 16 Nov. 2015.